Phase 3 study · Braveheart Bio · NCT07755904
Braveheart Bio's phase 3 BHB-1893 study for obstructive hypertrophic cardiomyopathy
About 210 adults are planned, and each is picked by chance to get BHB-1893 twice a day or metoprolol once a day. Matching placebos keep the participants and study team from knowing which, and the main results are measured at 24 weeks.
Get an email when it adds US sites
It is enrolling now. We send an email only when it adds a US site, so you hear if one opens nearer to you. Your email is used for nothing else.
Free email alert
Hear when Braveheart Bio's phase 3 BHB-1893 study opens near you
One email when it starts enrolling or lists a new site, with the sites and how to reach the study team. Nothing else.
Opening and new sites for this study only. Stop anytime. We never share your email. Privacy policy
Check the main requirements privately
These questions restate the study's public listing in plain words. Your answers stay on this device and are never sent. You can print a one-page summary to go over with your cardiologist.
1. Are you between 18 and 85 years old?
2. Has a cardiologist diagnosed you with obstructive hypertrophic cardiomyopathy (oHCM)?
The listing does not give the outflow gradient it requires. Your echocardiogram report usually shows it as the LVOT gradient, and the study measures it again.3. Are you comfortable at rest but get short of breath, tired or a racing heartbeat with everyday or light activity?
Doctors call this NYHA class II or III, a scale they use to grade heart symptoms. Your cardiologist may have written your class in your visit notes.4. Do you have another condition besides HCM that needs a beta-blocker or calcium channel blocker?
Examples of these medicines are atenolol, metoprolol, verapamil and diltiazem. Your cardiologist can say what each of your medicines is prescribed for.5. Have you ever had a bad reaction to a beta-blocker, or been told by a doctor not to take one?
6. Has a doctor told you that you have moderate or severe aortic stenosis, a narrowed aortic valve?
Your echocardiogram report would mention aortic stenosis if it was found.The study team also checks for these, which are easier to go over with your cardiologist:
- Resting systolic blood pressure, the top number, above 160 mmHg at screening
- Resting heart rate above 100 beats a minute at screening
- A leaky mitral valve with a cause other than the valve movement seen in obstructive HCM, in the study doctor's judgment
- A score on the KCCQ symptom questionnaire that meets the study's criteria at screening
- Heart ultrasound images clear enough for the study's echocardiograms
- Other criteria in the full study protocol, which the public listing does not spell out
Sites and contact
US sites from the public ClinicalTrials.gov record, refreshed every hour. Only the study team decides who can join.
- LIONHEART-HCM Site 0120Burlington, Massachusetts · Recruiting
- LIONHEART-HCM Site 0107Manhasset, New York · Recruiting
- LIONHEART-HCM Site 0126Rock Hill, South Carolina · Recruiting
- LIONHEART-HCM Site 0121Plano, Texas · Recruiting
Every site's own contact and the full eligibility list are on the official ClinicalTrials.gov listing for NCT07755904.
Questions people ask about Braveheart Bio's phase 3 BHB-1893 study
Is Braveheart Bio's phase 3 BHB-1893 study enrolling now?
ClinicalTrials.gov lists it as recruiting, as of its last update there on 2026-11-10. Only the study team can confirm whether a particular site is still taking people.
Where are the US sites for Braveheart Bio's phase 3 BHB-1893 study?
The listing names 4 US sites, in Massachusetts, New York, South Carolina, Texas. The full list is in the sites section of this page.
Who can join Braveheart Bio's phase 3 BHB-1893 study?
About 210 adults are planned, and each is picked by chance to get BHB-1893 twice a day or metoprolol once a day. The main listed requirements are in the pre-check on this page, starting with: adults 18 to 85 years old. Only the study team decides who can join.
How do I contact the Braveheart Bio's phase 3 BHB-1893 study team?
The listing names this contact: Study Director, (415) 707-6312, clinicaltrials@braveheart.bio. Each site may also list its own contact on ClinicalTrials.gov.
Is Trial Friend part of this study?
No. Trial Friend is independent of this study and its sponsor, Braveheart Bio. This page restates the public listing in plain words, and nothing here is medical advice; talk with your cardiologist about whether a study is right for you.
From the public ClinicalTrials.gov record NCT07755904, last updated there 2026-11-10. Questions checked against the listing on November 10, 2026. Trial Friend is independent of this study and its sponsor, and is not a medical provider. Nothing here is medical advice; talk with your cardiologist about whether a study is right for you.